MX2023002800A - Preparaciones de radio-224 y su progenie para uso en terapia con radionúclidos en combinación con inhibidores de reparación del adn. - Google Patents

Preparaciones de radio-224 y su progenie para uso en terapia con radionúclidos en combinación con inhibidores de reparación del adn.

Info

Publication number
MX2023002800A
MX2023002800A MX2023002800A MX2023002800A MX2023002800A MX 2023002800 A MX2023002800 A MX 2023002800A MX 2023002800 A MX2023002800 A MX 2023002800A MX 2023002800 A MX2023002800 A MX 2023002800A MX 2023002800 A MX2023002800 A MX 2023002800A
Authority
MX
Mexico
Prior art keywords
sup
inhibitor
radium
dna repair
combination
Prior art date
Application number
MX2023002800A
Other languages
English (en)
Inventor
Sara Westrøm
Jan A Alfheim
Original Assignee
Oncoinvent As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoinvent As filed Critical Oncoinvent As
Publication of MX2023002800A publication Critical patent/MX2023002800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una combinación de radio-224 (224Ra) y/o a progenies de 224Ra, así como a un inhibidor de reparación del ADN para su uso en el tratamiento contra el cáncer. El inhibidor de reparación del ADN puede ser, por ejemplo, un inhibidor de poli (ADP-ribosa) polimerasa (PARPi), un inhibidor de MGMT, un inhibidor de la proteína quinasa dependiente del ADN (inhibidor de ADN-PK), un inhibidor de la quinasa relacionada con la ataxia telangiectasia y Rad3 (ATR), un inhibidor de la quinasa de la ataxia telangiectasia mutada (ATM), un inhibidor de la quinasa Wee1 o un inhibidor de las quinasas de punto de control 1 y 2 (CHK1/2). El radio-224 (224Ra) y/o la progenie de 224Ra pueden estar incluidos en nano y/o micropartículas.
MX2023002800A 2020-09-15 2021-09-15 Preparaciones de radio-224 y su progenie para uso en terapia con radionúclidos en combinación con inhibidores de reparación del adn. MX2023002800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196215 2020-09-15
PCT/EP2021/075301 WO2022058338A1 (en) 2020-09-15 2021-09-15 Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors

Publications (1)

Publication Number Publication Date
MX2023002800A true MX2023002800A (es) 2023-04-21

Family

ID=72521402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002800A MX2023002800A (es) 2020-09-15 2021-09-15 Preparaciones de radio-224 y su progenie para uso en terapia con radionúclidos en combinación con inhibidores de reparación del adn.

Country Status (7)

Country Link
US (1) US20230330280A1 (es)
EP (1) EP4213826A1 (es)
JP (1) JP2023541635A (es)
CN (1) CN116171152A (es)
CA (1) CA3192409A1 (es)
MX (1) MX2023002800A (es)
WO (1) WO2022058338A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309280A (pt) * 2002-04-15 2005-02-22 Sloan Kettering Inst Cancer Terapia de combinação para o tratamento de câncer
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
EP3597665A1 (en) * 2011-04-01 2020-01-22 Yale University, Inc. Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair
EP3261681B1 (en) * 2015-02-26 2020-01-15 Sciencons AS Radiopharmaceutical solutions with advantageous properties
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN112912137B (zh) * 2018-11-01 2023-11-21 阿尔法陶医疗有限公司 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活

Also Published As

Publication number Publication date
WO2022058338A1 (en) 2022-03-24
CA3192409A1 (en) 2022-03-24
CN116171152A (zh) 2023-05-26
US20230330280A1 (en) 2023-10-19
EP4213826A1 (en) 2023-07-26
JP2023541635A (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
MX2019007444A (es) Metodos y sistemas para analisis de moleculas de acido nucleico.
CA3166153A1 (en) Base editors, compositions, and methods for modifying the mitochondrial genome
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
Li et al. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma
BR0215359A (pt) composições de aerogel e metálicas
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
BRPI0506677A (pt) sistemas e métodos para suportar a aprovação para estabelecer um comércio internacional de uma instituição de crédito, tal como uma linha de crédito ou uma conta corrente
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
HK1054980A1 (zh) 利用肝臟干細胞進行毒性分型
MX2021015450A (es) Reactivos y métodos para la replicación, transcripción y traducción en organismos semisintéticos.
PH12015502096A1 (en) Thymidine kinase diagnostic assay for gene therapy applications
WO2020005846A8 (en) Labeling of dna
Sabbattini et al. An H3K9/S10 methyl-phospho switch modulates Polycomb and Pol II binding at repressed genes during differentiation
MX2021001553A (es) Mutaciones novedosas que mejoran la actividad de escisión del adn de cpf1 de acidaminococcus sp.
MX2023002800A (es) Preparaciones de radio-224 y su progenie para uso en terapia con radionúclidos en combinación con inhibidores de reparación del adn.
Berjón-Otero et al. DNA polymerase from temperate phage Bam35 is endowed with processive polymerization and abasic sites translesion synthesis capacity
AR064673A1 (es) Proceso de conversion de hidrocarburos que incluye un sistema de reaccion con derivacion escalonada
AU2017250205A1 (en) Methods and systems for amplification in complex samples
DE60027735D1 (de) Genetische screeningverfahren
BR9916216A (pt) 4.5-azolo-oxindóis
NO20083387L (no) mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse
AU2001277648A1 (en) Plant cyclin-dependent kinase inhibitors
WO2022036312A3 (en) Inhibitors of ack1/tnk1 tyrosine kinase
WO2019079775A3 (en) A highly error-prone orthogonal dna replication system for targeted continuous evolution in vivo